Parkinson's Drugs Linked to Behavior Problems in Study
Hypersexuality, addictive gambling, binge eating noted with use of dopamine agonists
URL of this page: http://www.nlm.nih.gov/medlineplus/news/fullstory_110388.html(*this news item will not be available after 06/27/2011)
By Robert Preidt
Tuesday, March 29, 2011
Related MedlinePlus Pages
Drug Safety
Parkinson's Disease
TUESDAY, March 29 (HealthDay News) -- Parkinson's disease drugs called dopamine agonists appear to cause impulse control problems in almost one-quarter of patients, says a new study.
Previous research has linked dopamine agonists, which include Mirapex (pramipexole) and Requip (ropinirole), to impulse control disorders, such as gambling addiction and hypersexuality, and to compulsive behaviors, such as binge eating, overspending and excessive computer use.
In this study, Mayo Clinic researchers analyzed Parkinson's disease patient records over two years.
"What we found was that as many as 22 percent of patients during that two-year period had a new-onset impulse control disorder," lead investigator and neurology fellow Dr. Anhar Hassan said in a Mayo Clinic news release.
The higher the dose of dopamine agonist, the more likely a patient was to develop an impulse control disorder, the researchers found.
"One in four patients who were on a medium therapeutic dose of the medication had an impulse control disorder. For patients who were taking a higher range of the medication, about one in three developed an impulse control disorder," Hassan said.
The study was recently published online in the journal Parkinsonism and Related Disorders.
Patients taking dopamine agonists and their families need to watch for any behavior changes, Hassan said. Reducing the dose or going off the medication usually resolves behavior problems within a few days to a month.
SOURCE: Mayo Clinic, news release, March 23, 2011
HealthDay
Copyright (c) 2011 HealthDay. All rights reserved.
Parkinson's Drugs Linked to Behavior Problems in Study: MedlinePlus
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario